Brought to you by 
Bayer in respiratory alliance with spin-out Aerovance
06 Dec 2022
Executive Summary
In exchange for a 19.9% stake in its newly spun-off biopharmaceutical company Aerovance (therapeutics for respiratory, autoimmune, and inflammatory diseases), Bayer AG has signed over rights to two of Bayer Pharmaceuticals division's respiratory drug candidates, Phase I AER-001 and preclinical AER-002, and seven other preclinical respiratory candidates.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer in respiratory alliance with spin-out Aerovance
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice